Zydus Cadila gets nod to market Droxidopa capsules
Drug major, Zydus Cadila announced on Saturday that it has received a tentative approval from United States Food & Drug Administration (USFDA) to market Droxidopa capsules, in the strengths of 100 mg, 200 mg and 300 mg.
The medication is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition (neurogenic orthostatic hypotension-nOH). It can lessen the symptoms of low blood pressure when standing (orthostatic hypotension), such as dizziness and lightheadedness.
The company stated though its press release that the drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
Cadila Healthcare Limited manufactures and markets healthcare solutions ranging from formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, animal healthcare to cosmeceuticals. Its products are available in tablets, capsules, injections, liquids, dry syrups, powders, granules and ointments.
On Friday, the stock closed at Rs 332.15, down by 1.42 per cent or Rs 4.80 per share. The 52-week high is recorded at Rs 378 and the 52-week low is Rs 206.45 on BSE.